ASMB Valuation

Assembly Biosciences Inc

Add to Watchlist

Advanced Chart

24.700

-0.8(-3.137%)1D

Overview
Forecast
Valuation
Earnings

ASMB Relative Valuation

ASMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASMB is overvalued; if below, it's undervalued.

Historical Valuation

Assembly Biosciences Inc (ASMB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 11.33 is considered Overvalued compared with the five-year average of -1.79. The fair price of Assembly Biosciences Inc (ASMB) is between 5.92 to 13.13 according to relative valuation methord. Compared to the current price of 24.84 USD , Assembly Biosciences Inc is Overvalued By 89.15%.

Relative Value

Fair Zone

5.92-13.13

Current Price：24.84

89.15%

Overvalued

-7.17

Trailing

Forward

-6.86

EV/EBITDA

Assembly Biosciences Inc. (ASMB) has a current EV/EBITDA of -6.86. The 5-year average EV/EBITDA is -0.10. The thresholds are as follows: Strongly Undervalued below -1.60, Undervalued between -1.60 and -0.85, Fairly Valued between 0.65 and -0.85, Overvalued between 0.65 and 1.40, and Strongly Overvalued above 1.40. The current Forward EV/EBITDA of -6.86 falls within the Strongly Undervalued range.

-5.62

EV/EBIT

Assembly Biosciences Inc. (ASMB) has a current EV/EBIT of -5.62. The 5-year average EV/EBIT is 0.11. The thresholds are as follows: Strongly Undervalued below -1.82, Undervalued between -1.82 and -0.86, Fairly Valued between 1.07 and -0.86, Overvalued between 1.07 and 2.03, and Strongly Overvalued above 2.03. The current Forward EV/EBIT of -5.62 falls within the Strongly Undervalued range.

11.33

Assembly Biosciences Inc. (ASMB) has a current PS of 11.33. The 5-year average PS is 11.56. The thresholds are as follows: Strongly Undervalued below -37.78, Undervalued between -37.78 and -13.11, Fairly Valued between 36.23 and -13.11, Overvalued between 36.23 and 60.90, and Strongly Overvalued above 60.90. The current Forward PS of 11.33 falls within the Historic Trend Line -Fairly Valued range.

-6.25

P/OCF

Assembly Biosciences Inc. (ASMB) has a current P/OCF of -6.25. The 5-year average P/OCF is -0.94. The thresholds are as follows: Strongly Undervalued below -3.81, Undervalued between -3.81 and -2.37, Fairly Valued between 0.50 and -2.37, Overvalued between 0.50 and 1.93, and Strongly Overvalued above 1.93. The current Forward P/OCF of -6.25 falls within the Strongly Undervalued range.

-6.22

P/FCF

Assembly Biosciences Inc. (ASMB) has a current P/FCF of -6.22. The 5-year average P/FCF is -1.24. The thresholds are as follows: Strongly Undervalued below -4.06, Undervalued between -4.06 and -2.65, Fairly Valued between 0.18 and -2.65, Overvalued between 0.18 and 1.59, and Strongly Overvalued above 1.59. The current Forward P/FCF of -6.22 falls within the Strongly Undervalued range.

Assembly Biosciences Inc (ASMB) has a current Price-to-Book (P/B) ratio of 10.81. Compared to its 3-year average P/B ratio of 2.24 , the current P/B ratio is approximately 383.33% higher. Relative to its 5-year average P/B ratio of 1.65, the current P/B ratio is about 554.20% higher. Assembly Biosciences Inc (ASMB) has a Forward Free Cash Flow (FCF) yield of approximately -13.86%. Compared to its 3-year average FCF yield of -57.60%, the current FCF yield is approximately -75.93% lower. Relative to its 5-year average FCF yield of -59.64% , the current FCF yield is about -76.76% lower.

10.81

P/B

Median3y

2.24

Median5y

1.65

-13.86

FCF Yield

Median3y

-57.60

Median5y

-59.64

Competitors Valuation Multiple

The average P/S ratio for ASMB's competitors is 5.55, providing a benchmark for relative valuation. Assembly Biosciences Inc Corp (ASMB) exhibits a P/S ratio of 11.16, which is 101.14% above the industry average. Given its robust revenue growth of 12.81%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ASMB.O

Assembly Biosciences Inc

CytomX Therapeutics Inc

Abeona Therapeutics Inc

4.61

350.23M

FULC.O

Fulcrum Therapeutics Inc

Tonix Pharmaceuticals Holding Corp

4.27

-9.51%

259.73M

Performance Decomposition

Market capitalization of ASMB increased by 56.83% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.82 to -4.59.

The secondary factor is the Revenue Growth, contributed 12.81%to the performance.

Overall, the performance of ASMB in the past 1 year is driven by P/E Change. Which is more unsustainable.

12.81%

8.53M → 9.63M

Revenue Growth

-18.94%

-130.69 → -105.94

Margin Expansion

62.96%

-2.82 → -4.59

P/E Change

56.83%